BEIJING and SHANGHAI,
April 25, 2019 /PRNewswire/
-- CANbridge Pharmaceuticals Inc., a biopharmaceutical company
developing innovative drug candidates to treat underserved medical
conditions in China and other
markets, announced that it has appointed Glenn Hassan to the position of Chief Financial
Officer and Chief Business Officer, and Gerald F. Cox, MD, PhD, as Chief Development
Strategist and interim Chief Medical Officer, effective as of
April.
Mr. Hassan brings a broad range of banking and investment
experience in the healthcare and global therapeutics sector to his
role at CANbridge. Most recently, Mr. Hassan was Director,
Cross Border Healthcare Investment Banking at China Renaissance
Capital, focused on advising US and greater China life science companies on
capital-raising activities, and led equity capital market
activities for the healthcare sector. Before then, he was at
Leerink Capital Partners, where he was Senior Analyst/Portfolio
Manager, managing global funds in therapeutics, and at Citadel LLC
(Surveyor Capital) as Senior Analyst covering mid- and large-cap
global therapeutics equities. Earlier in his career he worked
at Fidelity Investments.
Mr. Hassan holds a Master of Science in Global Financial
Analysis from McCallum Graduate School of Business, Bentley College and a Bachelor of Science in
Business from Indiana University.
Dr. Cox comes to CANbridge most immediately from Gerald Cox Rare
Care Consulting, where he was founder, providing clinical
development solutions for rare disease treatments. Prior to that,
he was Chief Medical Officer for Editas Medicine, in Cambridge, where he led the clinical development of
CRISPR-based genome editing medicines to treat human diseases. Dr.
Cox also had a long stint at Sanofi Genzyme, also in Cambridge, culminating as Vice President, Rare
Disease Clinical Development, where he oversaw rare disease
clinical development programs, including for Cerdelga®; Olipudess
alfa; Hectoral®; Cerezyme® and Aldurazyme®, among others. Before
then, Dr. Cox held several senior medical R&D positions at
Genzyme, where he was the company's first clinical geneticist
recruited to oversee human clinical development programs for
several rare genetic diseases. Dr. Cox is a practicing geneticist
at Boston Children's Hospital.
Dr. Cox earned an MD, PhD in Biology from the University of California at San Diego, and a
Bachelor of Arts in Biology, from Harvard
College. He holds multiple patents and awards and has
authored scores of peer-reviewed publications, presentations and
book chapters.
"We are delighted to have two such extraordinarily high-caliber
executives stepping into leadership roles at CANbridge at this
crucial time in the company's trajectory as a commercial-stage
company with a robust clinical pipeline," said James Xue, PhD, Founder, Chairman and CEO,
CANbridge Pharmaceuticals. "With this strong partnership in
place, we will lead CANbridge's growth and transformation into a
Chinese sector leader with a global impact in rare disease and
specialty care."
Dr. Cox replaces Dr. May Orfali,
who left the company for personal reasons. Mr. Hassan assumes
Business Development responsibility previously held by Paul Wagner who is now serving as CEO of Forte
Biosciences.
About CANbridge Pharmaceuticals Inc.
CANbridge
Pharmaceuticals Inc. is a China-based biopharmaceutical company
accelerating development and commercialization of specialty
healthcare products for orphan diseases and targeted cancers,
focusing on products that are unavailable or address medical needs
that are underserved in the region.
CANbridge has been widely recognized as a leader in orphan
diseases in China. It has a global
partnership with WuXi Biologics to develop and commercialize
proprietary therapeutics for the treatment of rare genetic
diseases. In addition, it has an exclusive
licensing agreement
to commercialize Hunterase™, an enzyme
replacement therapy for the treatment of Hunter syndrome, developed
by GC Pharma and marketed in more
than ten countries worldwide. CANbridge also has an
oncology portfolio, which includes exclusive rights to develop and
commercialize Puma Biotechnology's NERLYNX® (neratinib), approved
in the US, and rights to other novel candidates.
For more on CANbridge Pharmaceuticals Inc., please go to
www.canbridgepharma.com.
Media Contact:
Deanne Eagle
Planet Communications
(917) 837-5866
View original content to download
multimedia:http://www.prnewswire.com/news-releases/canbridge-pharmaceuticals-appoints-chief-financial-officer-and-interim-chief-medical-officer-300838294.html
SOURCE CANbridge Pharmaceutical Inc.